BioSpace News Archive

HUTCHMED Limited and AstraZeneca PLC have initiated SANOVO, a China Phase III study of ORPATHYS®, an oral, potent, and highly selective MET tyrosine kinase inhibitor, in combination with AstraZeneca’s third-generation, irreversible epidermal growth factor receptor TKI, TAGRISSO® as a first-line treatment in certain non-small cell lung cancer patients whose tumors harbor EGFR mutation and overexpress MET.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the quarter ended June 30, 2021, and provided an update on clinical and corporate progress.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced participation in the following investor and scientific conferences in September.

Perrigo Company plc announced that it has signed a binding offer to acquire Héra SAS, a leading global consumer self-care company, from funds affiliated with private equity firm Astorg and Goldman Sachs Asset Management.

Bright Minds Biosciences, a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, announced that Ian McDonald, Chief Executive Officer, and Dr. Alan Kozikowski PhD, Chief Scientific Officer, will be presenting virtually at the H.C. Wainwright 23rd Annual Global Investment Conference.

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, announced that it has completed target enrollment of 21 patients in the Phase 2 proof-of-concept study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye.

NovaBay® Pharmaceuticals, Inc. announces that management will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021.

Vapotherm, Inc., updated its fiscal year 2021 revenue expectations and announced it will expand its disposables production capacity.

Orchard Therapeutics, a global gene therapy leader, announced that the company will webcast a virtual R&D Investor Event on Tuesday, September 14, 2021, from 7:00 a.m. to 8:00 a.m. ET.

Xenikos B.V., a clinical-stage biopharmaceutical company currently developing a novel therapy for treating immune related disorders, announced the closing of €40 million in convertible debt consisting of two equal tranches of €20 million.